Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
142.43
+3.27 (2.35%)
Mar 26, 2025, 4:00 PM EST - Market closed
Biogen Revenue
In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%. Biogen had revenue of $2.45B in the quarter ending December 31, 2024, with 2.87% growth.
Revenue (ttm)
$9.68B
Revenue Growth
-1.62%
P/S Ratio
2.14
Revenue / Employee
$1,272,308
Employees
7,605
Market Cap
20.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BIIB News
- 2 days ago - Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square - GlobeNewsWire
- 8 days ago - Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript) - Seeking Alpha
- 15 days ago - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients - GlobeNewsWire
- 16 days ago - Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 23 days ago - Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript) - Seeking Alpha
- 26 days ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 5 weeks ago - Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - Market Watch
- 5 weeks ago - Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Business Wire